US LNG exports surge but will buyers in China turn up?
Investing.com - Astrana Health (NASDAQ: ASTH) reported second quarter EPS of $0.19, $0.16 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $654.8M versus the consensus estimate of $639.1M.
Guidance
Astrana Health sees Q3 2025 revenue of $925.00M-$965.00M versus the analyst consensus of $943.70M.
Astrana Health sees FY 2025 revenue of $3.10B-$3.30B versus the analyst consensus of $3.18B.
Astrana Health’s stock price closed at $21.46. It is down -27.77% in the last 3 months and down -54.19% in the last 12 months.
Astrana Health saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Astrana Health’s stock price’s past reactions to earnings here.
According to InvestingPro, Astrana Health’s Financial Health score is "good performance".
Check out Astrana Health’s recent earnings performance, and Astrana Health’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar